PipelineReview.com38m
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
KT-621 has demonstrated dupilumab-like activity and was well tolerated ina wide variety of preclinical models of TH2 diseases ...
PipelineReview.com45m
Novavax’s Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU
GAITHERSBURG, MD, USA I October 9, 2024 I Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today ...
PipelineReview.com1h
InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-488 Meet Primary Endpoint in Psoriasis Patients
BEIJING, China I October 09, 2024 I InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and ...
PipelineReview.com16h
U.S. Food and Drug Administration (FDA) accepts New Drug Application for elinzanetant
BERLIN, Germany I October 09, 2024 I Bayer today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application ...
PipelineReview.com16h
Boehringer Ingelheim and Circle Pharma announce new research collaboration to develop a novel precision cancer treatment
INGELHEIM, Germany and SOUTH SAN FRANCISCO, CA, USA I October 09, 2024 I Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration ...
PipelineReview.com23h
Alpha Fusion Accelerates Astatine-based Drug Discovery with Series B Funding
OSAKA, Japan I October 9, 2024 I Alpha Fusion, Inc. (CEO: Sunao Fujioka, headquartered in Kita-ku, Osaka), has raised a total of ¥1.02 billion through a ...
PipelineReview.com1d
Phanes Therapeutics Announces First Patient Dosed in Clinical Study of PT886 in Combination with KEYTRUDA® (pembrolizumab)
SAN DIEGO, CA, USA I October 8, 2024 I Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and ...